Date: 2015-09-30
Type of information: Nomination
Compound:
Company: Sarepta Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 30, 2015, Sarepta Therapeutics announced the appointment of Jean-Paul Kress, M.D., to the Company’s Board of Directors. Jean-Paul Kress, M.D., is the recently appointed Head of North America, Sanofi Genzyme Specialty Care Business Unit (Multiple Sclerosis, Oncology & Immunology). Prior to this appointment, Jean-Paul served as the President and CEO of Sanofi Pasteur MSD. During his tenure with Sanofi Pasteur MSD, a joint venture between Sanofi Pasteur and Merck & Co, Jean-Paul embarked on a series of changes to reshape the organization to better meet the challenges of the rapidly changing vaccine industry and to drive the launches of a number of innovative new products. His ability to mobilize the organization to focus on the most critical priorities resulted in a turnaround of the business and provided a firm foundation for sustainable growth. A strong advocate for the socio-economic value of vaccination, Jean-Paul was actively involved in the development of health policy across the EU with a focus on disease prevention.
Prior to his work at Sanofi Pasteur MSD, Jean-Paul was Vice President and General Manager in France for Gilead, a major US-based biopharmaceutical company specialized in therapeutics for life-threatening diseases such as HIV. He joined Gilead in California in 2006 as Vice President, US Sales and Marketing.
Jean-Paul Kress holds a MD Degree from Faculté Necker-Enfants Malades in Paris, France, and is an alumnus of the prestigious Ecole Normale Supérieure in Paris, France. He sits on the Board of Directors of CNE (the ENS Alumni association).
Financial terms:
Latest news:
